Clinical Cancer Proteomics offers great promise for unveiling the complex molecular events of tumorigenesis. Proteomic technologies are being used for studies of dynamic protein expression, post-translational modifications, cellular and sub-cellular protein distribution, and protein-protein interactions that have culminated in the identification of many cancer-related biomarkers and potential new drug targets. Emerging proteomic technologies such as, iTRAQ-Multidimensional Liquid Chromatography and Tandem Mass Spectrometry enable the unprecedented large-scale sequencing of tryptic peptides, and identification and quantification of proteins in precancerous and cancerous tissue samples with mass Spectrometry. Using head and neck cancer as a prototype the application of proteomic technologies for novel cancer biomarkers and drug target identification will be discussed. Our primary method for investigation of the differential expression of proteins in head and neck cancer is based on multidimensional LC-MS/MS analysis of biological samples labeled with mass tags. This strategy has been used for unraveling the perturbed signaling pathways and biological networks in head and neck cancer and consequent discovery of potential cancer markers. The application of high-throughput protein evaluation with a subset of predefined targets, identified through proteomics and pathway analysis in animal models and human tissues, can potentially yield novel biomarkers reflecting cancer development, establishing earlier detection strategies, and permitting monitor of responses to therapy as well as identifying molecular targets for designing new therapeutic strategies.
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Development of an HPLC Method for the Determination of Capsaicins in Human Plasma
Thomas Hartley, Brian Stevens and Kiran Ahuja School of Human Life Sciences, University of Tasmania, Launceston, Tasmania 7250, Australia
There have been numerous reports documenting the physiological effects/benefits of capsaicins but we noted that there were no formal dose response data; at best measured response versus 'chilli heat dose' expressed in Scoville Units data have been published. As a result we decided to develop a suitable analytical method for the analysis of blood samples. After an extensive review of the literature and several pilot studies we have determined some practical parameters for a routine HPLC assay of capsaicins in blood plasma and chilli containing food items. 10mL glass tubes were coated with 40ng of Oestradiol, the internal standard. 2mL of plasma were placed into these tubes, 1mL of phosphate buffer was added, mixed and then 4mL of 1-chlorobutane was added as the extractant. After 20 minutes of gentle mixing the tubes were centrifuged at 4 o C. 4.5mL of the organic layer was evaporated to dryness and then taken up in 150μL of acetonitrile, (ACN). This was applied to a Phenomenex C18(2) column via a 20uL sample loop and run isocratically with 60:40 ACN:Water. The absorbance was monitored at 205nm. The retention times for Capsaicin and Dihydrocapsaicin were 82 and 162 seconds respectively with CVs of 1.6%. Peak heights were measured. Preliminary results from six subjects indicated that Capsaicin ranged from 5 to 40 ng/mL and Dihydrocapsaicin ranged from 6 to 8 ng/mL. Total elution time was 7 minutes followed by a 20 minute column flush. The initial results have demonstrated that the method will be suitable for research work after the completion of minor refinements to the techniques. Vitreous humor has been well recognized as an important investigative fluid in forensic pathology, especially postmortem interval (PMI) determinations. The objective of the study was to evaluate the utility of vitreous biochemistry in estimating PMI and devise appropriate vitreous biochemistry based formulae to aid PMI estimations. Vitreous humor samples were collected from a total of 61 subjects (Female, 22; Male, 39; Age, 16 to 95 years) with precisely documented time of death (4.5 to 84.3 hours). Right and left eye vitreous humor samples were collected separately and the mean values were used for statistical analyses. The supernatant was analyzed for sodium, potassium, chloride, calcium, magnesium, urea, creatinine, glucose and lactate on an LX-20 Analyzer (Beckman-Coulter). Vitreous humor hypoxanthine and xanthine were analyzed using a colorimetric method. The statistical analyses were carried out using linear regression analysis and Statistical Package for Social Sciences (SPSS) for Windows™. It was observed that there was a significant correlation between vitreous potassium (R, 0.731; P, <0.0001), hypoxanthine, (R, 0.450; P, <0.0001), xanthine (R, 0.590; P, <0.0001), lactate (R, 0.508; P, <0.0001), calcium (R, 0.33; P, <0.01) and PMI. The mean values of vitreous biochemical constituent were used as the dependent variable to calculate the estimated PMI. The resulting formulae, derived from the linear regression equation, for PMI estimation were: for potassium (6.41 (K On comparing the actual PMI and the estimated PMI calculated using the formulae, it was found that the correlation was the highest for potassium based formulae (R, 0.731; P< 0.0001). These results suggest that the vitreous potassium, hypoxanthine, xanthine, lactate and calcium are all significantly correlated with PMI. The proposed formulae for estimating PMI may be used in conjunction with vitreous potassium to possibly enhance PMI estimations by narrowing the error margin. He was also a Councilor of the Canadian Society for Clinical Investigation and has chaired its By-laws committee. Dr. Kalra's research interest is in the area of oxidative stress in the pathogenesis of heart failure and atherosclerosis. He has been a pioneer in establishing guidelines for thyoraid-function testing, quality assurance program and laboratory utilization in health care. Dr. Kalra is also an advocate for quality care with active research interests in the area of quality care and patient safety. E-mail: jay.kalra@usask.ca jay.kalra@saskatoonhelthregion.ca Phone: (306) 
